Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib in DCIS of the Breast
NCT00082667Phase 2Terminated
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Start
- Oct 2002
- Primary completion
- Jul 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ductal carcinoma in situ (DCIS) comparing Gefitinib with Placebo (2 arms). Primary endpoint: Epidermal Growth Factor Receptor Pathway Biomarker Modulation. Started Oct 2002; status: terminated.
02
Drugs
03
Conditions
ductal carcinoma in situ (DCIS)
Beyond the preview
Go deeper on NCT00082667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00082667.